3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Dexamethasone
64
Lenalidomide
37
daratumumab
35
Bortezomib
32
pomalidomide
30
Specimen Handling
25
carfilzomib
23
Biopsy
23
Cyclophosphamide
20
Magnetic Resonance Spectroscopy
18
Calcium Dobesilate
18
isatuximab
13
fludarabine
11
dexamethasone acetate
11
dexamethasone 21-phosphate
11
auricularum
11
talquetamab
10
iberdomide
10
selinexor
8
belantamab mafodotin
8
Melphalan
8
tocilizumab
7
X-Rays
7
elotuzumab
6
fludarabine phosphate
5
Nuclear Medicine Department, Hospital
5
trametinib
4
pembrolizumab
4
Sirolimus
4
Nivolumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Hizentra
×
30 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled